MACCIO', ANTONIO PIETRO MARIO
 Distribuzione geografica
Continente #
EU - Europa 129.316
NA - Nord America 13.450
AS - Asia 5.754
SA - Sud America 930
Continente sconosciuto - Info sul continente non disponibili 519
AF - Africa 156
OC - Oceania 6
AN - Antartide 2
Totale 150.133
Nazione #
IT - Italia 125.880
US - Stati Uniti d'America 13.218
SG - Singapore 2.116
CN - Cina 1.988
UA - Ucraina 916
SE - Svezia 730
BR - Brasile 683
VN - Vietnam 553
DE - Germania 449
FI - Finlandia 373
GB - Regno Unito 328
FR - Francia 293
HK - Hong Kong 264
IN - India 174
KR - Corea 159
CA - Canada 125
BD - Bangladesh 108
AR - Argentina 96
NL - Olanda 60
RU - Federazione Russa 59
ID - Indonesia 51
MX - Messico 45
PK - Pakistan 39
TR - Turchia 39
ZA - Sudafrica 39
EC - Ecuador 38
IQ - Iraq 38
JP - Giappone 36
AT - Austria 33
CO - Colombia 33
PL - Polonia 32
PH - Filippine 31
IE - Irlanda 29
MA - Marocco 28
ES - Italia 26
UZ - Uzbekistan 22
SA - Arabia Saudita 21
EG - Egitto 19
VE - Venezuela 19
CL - Cile 18
IR - Iran 17
JM - Giamaica 15
KE - Kenya 15
PE - Perù 15
BE - Belgio 14
CH - Svizzera 14
TN - Tunisia 14
TH - Thailandia 13
CR - Costa Rica 11
MY - Malesia 10
PY - Paraguay 10
RO - Romania 10
UY - Uruguay 10
DZ - Algeria 9
EU - Europa 9
LT - Lituania 9
JO - Giordania 8
KZ - Kazakistan 8
TT - Trinidad e Tobago 8
AL - Albania 7
CZ - Repubblica Ceca 7
DK - Danimarca 7
NP - Nepal 7
AZ - Azerbaigian 6
BG - Bulgaria 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
RS - Serbia 6
AU - Australia 5
HU - Ungheria 5
LB - Libano 5
LK - Sri Lanka 5
OM - Oman 5
PS - Palestinian Territory 5
AE - Emirati Arabi Uniti 4
EE - Estonia 4
KW - Kuwait 4
PR - Porto Rico 4
PT - Portogallo 4
BB - Barbados 3
BZ - Belize 3
CI - Costa d'Avorio 3
ET - Etiopia 3
GR - Grecia 3
GT - Guatemala 3
MU - Mauritius 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
AQ - Antartide 2
BH - Bahrain 2
BS - Bahamas 2
BW - Botswana 2
BY - Bielorussia 2
CM - Camerun 2
GH - Ghana 2
HR - Croazia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
MG - Madagascar 2
MN - Mongolia 2
Totale 149.585
Città #
Cagliari 121.797
Uta 3.362
Fairfield 1.282
Woodbridge 1.098
Singapore 1.069
Ashburn 1.062
Houston 774
Dallas 699
San Jose 668
Chandler 628
Boardman 603
Nyköping 544
Seattle 539
Ann Arbor 535
Jacksonville 523
Wilmington 505
Cambridge 421
Beijing 356
Council Bluffs 283
New York 244
Hong Kong 241
Helsinki 227
Los Angeles 225
Dearborn 224
Ho Chi Minh City 180
Hefei 177
Santa Clara 170
Lauterbourg 168
Nanjing 167
Boston 162
Seoul 136
The Dalles 123
Hanoi 114
Buffalo 113
Guangzhou 91
San Diego 88
Shanghai 86
Milan 80
Dong Ket 68
London 66
Menlo Park 57
Shenyang 53
São Paulo 50
Toronto 49
Rome 46
Changsha 43
Redwood City 43
Nanchang 42
Redondo Beach 42
Tianjin 42
Chicago 41
Frankfurt am Main 40
Columbus 39
Orem 37
Phoenix 37
Nuremberg 36
Atlanta 34
Jinan 33
Hebei 32
Jiaxing 32
Chennai 31
Pune 30
Tokyo 30
Norwalk 28
Verona 27
Rio de Janeiro 24
Orange 23
Warsaw 23
Mountain View 22
Munich 22
Montreal 21
Zhengzhou 21
Haiphong 20
San Francisco 20
Baghdad 19
Hangzhou 19
Johannesburg 19
Vienna 19
Denver 18
Amsterdam 17
Da Nang 17
Tashkent 17
Auburn Hills 16
Brooklyn 16
Belo Horizonte 14
Buenos Aires 14
Charlotte 14
Mumbai 14
Nairobi 14
Brussels 13
Manchester 13
Quito 13
Sassari 13
Wuhan 13
Ankara 12
Detroit 12
Ningbo 12
Philadelphia 12
Dhaka 11
Dublin 11
Totale 141.450
Nome #
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients 3.351
Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach 2.545
Feasibility and safety of total laparoscopic hysterectomy for huge uteri without the use of uterine manipulator: description of emblematic cases 2.476
Randomized phase III clinical trial of a combined treatment with carnitine plus celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2.437
Abdominal leiomyosarcomatosis after surgery with external morcellation for occult smooth muscle tumors of uncertain malignant potential: A case report 2.269
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.201
Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity 2.194
Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches 2.063
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6 2.045
A PET-positive rapidly growing mass of the abdominal wall after cesarean section with an unexpected diagnosis of vernix caseosa granuloma: a case report 1.988
Advances in pharmacologic strategies for cancer cachexia 1.907
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 1.892
Combined laparoscopic excisional surgery for synchronous endometrial and rectal adenocarcinoma in an obese woman 1.863
Laparoscopic removal of a very large uterus weighting 5320 g is feasible and safe: a case report. 1.808
Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia 1.795
Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer 1.792
Krill oil to improve blood lipids status in advanced cancer patient with cachexia 1.784
The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study 1.740
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice. 1.733
Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up 1.731
Successful laparoscopic management of a giant ovarian cyst 1.730
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia 1.726
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results 1.720
Future prospects for PD-1 targeting, macrophage infiltration, and IDO pathway activation in patients with sarcomas 1.719
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy 1.693
A multitargeted treatment approach for anemia and cachexia in metastatic castration-resistant prostate cancer 1.668
Surprising results of a supportive integrated therapy in myelofibrosis 1.614
Defibrotide in the COVID-19 coagulopathy: what is the timing? 1.587
Large twisted ovarian fibroma associated with Meigs' syndrome, abdominal pain and severe anemia treated by laparoscopic surgery 1.584
Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures 1.572
Laparoscopic hysterectomy as optimal approach for 5400 grams uterus with associated polycythemia: A case report 1.548
L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer 1.524
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? 1.488
An interdisciplinary approach for laparoscopic removal of a large retroperitoneal pelvic schwannoma attached to vital vessels: A case report 1.474
Feasibility and safety of total laparoscopic hysterectomy for uteri weighing from 1.5 kg to 11.000 kg 1.419
Editorial: Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes 1.363
EFFICACY AND SAFETY OF A TWO DRUG-COMBINATION REGIMEN FOR CANCER-RELATED CACHEXIA IN THE CLINICAL PRACTICE 1.330
(0) Save to: more options IMPROVEMENT OF PHYSICAL ACTIVITY AS AN ALTERNATIVE OBJECTIVE VARIABLE TO MEASURE TREATMENT EFFECTS OF ANTI CACHEXIA THERAPY IN CANCER PATIENTS 1.220
Role of interleukin-2 (IL-2) in cancer-related immune deficiency: in vitro response to IL-2, production of IL-2, and IL-2 receptor expression in patients with advanced cancer 1.172
Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status 1.155
Quantitative evaluation of oxidative stress, chronic inflammatory indexes, and leptin in cancer patients: Correlation with stage and performance status. 1.072
Peripheral blood lymphocyte response to recombinant and non-recombinant interleukin 2 in previously treated patients with Hodgkin's disease, long-time off-therapy 1.013
New perspective on the nutritional approach to cancer-related anorexia/cachexia: Preliminary results of a randomised phase III clinical trial with five different arms of treatment 1.004
null 998
Interleukin 2 (IL 2) and cancer. In vitro response to exogenous R and non-R IL 2 by PHA-activated and non-PHA-activated PBMC from patients with cancer 963
Blocking inflammation to improve immunotherapy of advanced cancer 955
Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients 945
Laparoscopic management of a giant mucinous benign ovarian mass weighing 10150 grams: A case report 930
Interleukin 2 (IL 2) relationships with the cancer-related immunodeficiency: in vitro response to exogenous IL 2 by PHA-activated and non PHA-activated peripheral blood mononuclear cells from cancer patients 920
Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity 876
The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications - a review 874
Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases 866
Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer 863
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress 849
Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas 840
null 819
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 819
Successful pregnancy following myomectomy of a giant uterine myoma: role of a combined surgical approach 808
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress 789
A PHASE II STUDY WITH ANTIOXIDANTS, BOTH IN THE DIET AND SUPPLEMENTED, PHARMACO-NUTRITIONAL SUPPORT,PROGESTAGEN AND ANTI-COX-2 SHOWING EFFICACY AND SAFETY IN PATIENTS WITH CANCER-RELATED ANOREXIA-CACHEXIA AND OXIDATIVE STRESS 788
Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report 787
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 785
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment 783
Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment 773
Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer 768
Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer 757
Experimental drugs for chemotherapy-and cancer-related anemia 750
Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients 741
Current medications for cancer cachexia 740
Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature 712
null 709
Laparoscopic management of isolated nodal recurrence in gynecological malignancies is safe and feasible even for large metastatic nodes up to 8 cm: A prospective case series 701
Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique 700
Novel technique of extracorporeal intrauterine morcellation after total laparoscopic hysterectomy: Three emblematic case reports 695
Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients 683
Randomised Phase III Clinical Trial of a Combined Treatment With Carnitine plus Celecoxib +/- Megestrol Acetate for Patients With Cancer-related Anorexia/cachexia Syndrome 661
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity 637
Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation 633
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy 632
Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites 626
Managing cancer-related anorexia/cachexia 618
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs 617
Cancer-related cachexia and oxidative stress: beyond current therapeutic options 611
Correlation of Leptin, Proinflammatory Cytokines and Oxidative Stress with Tumor Size and Disease Stage of Endometrioid (Type I) Endometrial Cancer and Review of the Underlying Mechanisms 601
Serum levels of leptin and proinflammatory cytokines in patients with advanced stage cancer at different sites 596
The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression 595
Decrease in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a predictive and prognostic marker in advanced ovarian cancer 594
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes 593
Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites 591
The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone 591
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment 586
Cachexia as evidence of the mechanisms of resistance and tolerance during the evolution of cancer disease 583
Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review 574
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report 571
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 571
Cachexia and oxidative stress in cancer: an innovative therapeutic management 567
Multitargeted treatment of cancer cachexia 567
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 566
Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma 562
Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia 560
Totale 115.898
Categoria #
all - tutte 230.308
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 230.308


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.488 0 514 450 439 721 447 469 481 605 537 702 1.123
2022/202313.193 1.054 1.398 1.170 1.002 925 1.439 747 1.423 965 978 1.353 739
2023/202415.777 994 639 532 1.061 1.520 2.821 2.198 1.004 749 1.070 1.661 1.528
2024/202519.801 2.461 3.737 3.090 3.232 1.625 2.406 1.441 195 420 384 400 410
2025/202610.675 593 534 1.406 998 745 650 1.876 429 870 1.514 693 367
2026/2027712 145 567 0 0 0 0 0 0 0 0 0 0
Totale 150.133